Abstract: The invention provides, inter alia, improved lipid formulations used to generate lipid-encapsulated gas microspheres, and methods of their use.

Abstract: Provided herein are gas bubble populations optimized for certain imaging and therapeutic ultrasound uses, methods of preparing such populations, and methods of use thereof.

Abstract: A method of imaging, the method comprising administering, to a subject, a compound of Structure Alpha, of the formula: or a pharmaceutically acceptable salt thereof, wherein: n is 0; R, R1, and R3 are independently selected from the group consisting of H, OR4, F, Cl, Br, I, CF3, alkyl (C1-C4), aryl, heteroaryl, C(?O)R4, CO2R4, N(R4)2, CN, C(?NR4)OR5, NR4C(?NR5)NHR6, C(?NR4)NHR5, C(?O)NHR4, NR4C(?O)NR5, NR4NR5, SO2OR4, and imaging moiety Im; R2 is absent; R4, R5, and R6 are independently selected from the group consisting of H, alkyl, aryl and heteroaryl substituents; wherein the alkyl, aryl, or heteroaryl may be substituted with imaging moiety Im, wherein optionally any two of R4, R5, and R6 form a cyclic structure selected from the group consisting of —CH2—CH2—, —CH2—CH2—CH2, —CH?CH—, —X?CH—, and —X—CH?CH—, wherein X is selected from the group consisting of O, NH, and NR7, and wherein R7 is selected from the group consisting of alkyl, aryl, and heteroaryl substituents; W, X, Y and Z are independently s

Abstract: The present invention provides compounds with imaging moieties for imaging a subject. The present invention also relates to systems, compositions, and methods for the synthesis and use of imaging agents, or precursors thereof. An imaging agent precursor may be converted to an imaging agent using the methods described herein. In some cases, a composition or plurality of imaging agents is enriched in 18F. In some cases, an imaging agent may be used to image an area of interest in a subject, including, but not limited to, the heart, cardiovascular system, cardiac vessels, brain, and other organs.

Abstract: The present invention relates to systems, compositions, and methods for the synthesis and use of imaging agents, or precursors thereof. An imaging agent precursor may be converted to an imaging agent using the methods described herein. In some cases, the imaging agent is enriched in 18F. In some cases, an imaging agent may be used to image an area of interest in a subject, including, but not limited to, the heart, cardiovascular system, cardiac vessels, brain, and other organs. In some embodiments, methods and compositions for assessing perfusion and innervation mismatch in a portion of a subject are provided.

Abstract: Provided herein are improved methods for preparing phospholipid formulations including phospholipid UCA formulations.

Abstract: Novel compounds that find use as imaging agents within nuclear medicine applications (PET imaging) for imaging of cardiac innervation are disclosed. These PET based radiotracers may exhibit increased stability, decreased NE release (thereby reducing side effects), improved quantitative data, and/or high affinity for VMAT over prior radiotracers. Methods of using the compounds to image cardiac innervation are also provided. In some instances the compounds are developed by derivatizing certain compounds with 18F in a variety of positions: aryl, alkyl, a keto, benzylic, beta-alkylethers, gamma-propylalkylethers and beta-proplylalkylethers. Alternatively or additionally, a methyl group a is added to the amine, and/or the catechol functionality is either eliminated or masked as a way of making these compounds more stable.

Abstract: The invention provides, inter alia, improved lipid formulations used to generate lipid-encapsulated gas microspheres, and methods of their use.

Abstract: Provided herein are methods and devices for identifying and/or distinguishing UCA formulations and specifically activating such formulations to produce UCA suitable for in vivo use.

Abstract: Provided herein are methods and related compositions, including kits, for the improved synthesis, preparation and/or storage of [18F]DCFPyL. Also provided are methods of using [18F]DCFPyL, such as for imaging.

Abstract: Provided herein are improved methods for preparing phospholipid formulations including phospholipid UCA formulations.

Abstract: Provided herein are methods and devices for identifying and/or distinguishing UCA formulations and specifically activating such formulations to produce UCA suitable for in vivo use.

Abstract: The present invention provides compounds with imaging moieties for imaging a subject. The present invention also relates to systems, compositions, and methods for the synthesis and use of imaging agents, or precursors thereof. An imaging agent precursor may be converted to an imaging agent using the methods described herein. In some cases, a composition or plurality of imaging agents is enriched in 18F. In some cases, an imaging agent may be used to image an area of interest in a subject, including, but not limited to, the heart, cardiovascular system, cardiac vessels, brain, and other organs.

Abstract: Provided herein are improved methods for preparing phospholipid formulations including phospholipid UCA formulations.

Abstract: Provided herein are improved methods for preparing phospholipid formulations including phospholipid UCA formulations.

Abstract: Provided herein are improved methods for preparing phospholipid formulations including phospholipid UCA formulations.

Abstract: Provided herein are improved methods for preparing phospholipid formulations including phospholipid UCA formulations.

Abstract: The present invention provides compounds with imaging moieties for imaging a subject. The present invention also relates to systems, compositions, and methods for the synthesis and use of imaging agents, or precursors thereof. An imaging agent precursor may be converted to an imaging agent using the methods described herein. In some cases, a composition or plurality of imaging agents is enriched in 18F. In some cases, an imaging agent may be used to image an area of interest in a subject, including, but not limited to, the heart, cardiovascular system, cardiac vessels, brain, and other organs.

Abstract: Provided herein are improved methods for preparing phospholipid formulations including phospholipid UCA formulations.

Abstract: The invention provides, inter alia, improved lipid formulations used to generate lipid-encapsulated gas microspheres, and methods of their use.